Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: A prospective study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 3, 2012, Pages 368-379

  Hassall, E ^a,g   Shepherd, R ^b   Koletzko, S ^c   Radke, M ^d,h   Henderson, C ^e   Lundborg, P ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e OXFORD PHARMAGENESIS LTD   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g Sutter Pacific Medical Foundation   (United States)

^h Children's Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; ERADICATION THERAPY; ESOPHAGUS ATRESIA; GASTROSTOMY; GLYCOGEN STORAGE DISEASE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INTESTINAL DYSMOTILITY; LONG TERM CARE; MAINTENANCE THERAPY; MORNING DOSAGE; NEUROLOGIC DISEASE; OTITIS MEDIA; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; RHINITIS; SIDE EFFECT; STOMACH BIOPSY; TREATMENT DURATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESOPHAGITIS; FEMALE; HUMANS; INFANT; LONG-TERM CARE; MALE; OMEPRAZOLE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855339916     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04950.x     Document Type: Article

References (32)

1. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M,. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008; 46: 524-33.
2. Gunasekaran TS, Hassall EG,. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123: 148-54. (Pubitemid 23185219)
3. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137: 800-7.
4. Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM,. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006; 42: 384-91. (Pubitemid 43841020)
5. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L,. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 (Suppl. 4): S308-18. (Pubitemid 35416901)
6. Hassall E,. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146: S3-12. (Pubitemid 40332489)
7. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2009; 49: 498-547.
8. Donnellan C, Sharma N, Preston C, Moayyedi P,. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2: CD003245.
9. Boccia G, Manguso F, Miele E, Buonavolont'a R, Staiano A,. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 192: 1291-7. (Pubitemid 46802013)
10. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
11. Dixon MF, Genta RM, Yardley JH, Correa P,. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
12. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200. (Pubitemid 19070318)
13. Hassall E,. Barrett's esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr 1993; 16: 345-64. (Pubitemid 23143760)
14. Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, Meuwissen SG,. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998; 152: 1113-8. (Pubitemid 28509391)
15. Hassall E, Kerr W, El-Serag HB,. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 262-7.
16. Sherman PM, Hassall E, Fagundes-Neto U, et al. A global evidence-based consensus on the definition of gastroesophageal reflux disease in children. Am J Gastroenterol 2009; 104: 1278-95.
17. Hassall E,. Esophagitis and Barrett's esophagus: unifying the definitions and diagnostic approaches, with special reference to esophageal atresia. J Pediatr Gastroenterol Nutr 2011; 52: S23-6.
18. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85. (Pubitemid 40476458)
19. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57: 1354-9.
20. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: e817-20. (Pubitemid 46071346)
21. Dial MS,. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104 (Suppl. 2): S10-6.
22. 2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117: e137-42. (Pubitemid 46071566)
23. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M,. Multicenter, double-blind, randomized, placebo-controlled trial assessing efficacy & safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154: 514-20.
24. FDA Communication. Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). 2011. Available at:. Accessed December 3, 2011.
25. Insogna KL,. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009; 104 (Suppl. 2): S2-4.
26. McColl KE,. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104 (Suppl. 2): S5-9.
27. Valuck RJ, Ruscin JM,. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422-8. (Pubitemid 38609284)
28. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342-63.
29. Drumm B, Koletzko S, Oderda G,. Helicobacter pylori infection in children: a consensus statement. European Paediatric Task Force on Helicobacter pylori. J Pediatr Gastroenterol Nutr 2000; 30: 207-13. (Pubitemid 30366200)
30. Gold BD, Colletti RB, Abbott M, et al. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000; 31: 490-7.
31. Rindi G, Solcia E,. Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors. Gastroenterol Clin North Am 2007; 36: 851-65. (Pubitemid 350051708)
32. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H,. Gastric histology in children treated with proton pump inhibitors (PPIs) long-term, with emphasis on ECL hyperplasia. Aliment Pharmacol Ther 2011; 33: 829-36.